- $10.89m
- $27.81m
- $8.51m
- 24
- 33
- 63
- 33
Annual balance sheet for Evogene, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 48.2 | 53.9 | 35.4 | 31.1 | 15.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.59 | 2.93 | 1.83 | 3.33 | 2.85 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 51.8 | 56.9 | 37.8 | 34.5 | 21.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.94 | 4.18 | 4.07 | 3.44 | 4.25 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 71.9 | 76.3 | 56.1 | 51.1 | 39.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 9.68 | 6.88 | 5.63 | 6.94 | 18.7 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 25.9 | 22.7 | 28.2 | 39 | 41.3 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 46 | 53.7 | 27.9 | 12.1 | -1.45 |
| Total Liabilities & Shareholders' Equity | 71.9 | 76.3 | 56.1 | 51.1 | 39.9 |
| Total Common Shares Outstanding |